Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temporary mycophenolate withdrawal around influenza vaccination in systemic lupus erythematosus
ACTRN12623000397617Phase 2Recruiting
- Sponsor
- Monash Health
- Start
- May 2023
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of mycophenolate and influenza vaccine in systemic lupus erythematosus (SLE) (2 arms), sponsored by Monash Health. Primary endpoint: Influenza antibody titre response. Started May 2023; status: recruiting.
02
Drugs
mycophenolateinfluenza vaccine
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ACTRN12623000397617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000397617.